AU$23m market cap
AU$0.32 last close
Kazia Therapeutics has two clinical stage anti-cancer drugs: GDC-0084 (targeting glioblastoma) and Cantrixil (targeting ovarian cancer). GDC-0084 was inlicensed from Genentech, and Kazia is seeking other in-licence opportunities.
Investment summary
Kazia Therapeutics’ FY19 financial results show cash of A$5.4m and an operational cash use of A$6.7m. The 20-patient efficacy cohort in the lead GDC-0084 Phase IIa study should report data in Q419. Kazia has announced a new trial collaborating with the prestigious MSK hospital in NY to look at GDC-0084 in PI3K mutated brain metastases in conjunction with radiotherapy. Initial efficacy data from the Cantrixil ovarian cancer Phase I is also due in Q419. Our base-case value, updated for year-end cash, is A$137m.
Y/E Jun |
Revenue (A$m) |
EBITDA (A$m) |
PBT (A$m) |
EPS (c) |
P/E (x) |
P/CF (x) |
|---|---|---|---|---|---|---|
| 2018A | 2.9 | (10.9) | (11.0) | (22.2) | N/A | N/A |
| 2019A | 1.5 | (7.6) | (7.7) | (12.9) | N/A | N/A |
| 2020E | 1.5 | (8.7) | (8.7) | (14.0) | N/A | N/A |
| 2021E | 1.5 | (11.1) | (11.1) | (17.9) | N/A | N/A |
| Last updated on 20/06/2019 | ||||||
Industry outlook
Kazia Therapeutics is listed on the ASX and NASDAQ. Its two drug technology platforms are GDC-0084, a PI3K inhibitor licensed from Genentech, and a Cantrixil, a third-generation benzopyrans.
Last updated on 20/06/2019
Sector |
|---|
| Healthcare |
Share price graph
Balance sheet |
|
|---|---|
| Forecast net debt (A$m) | 8.3 |
| Forecast gearing ratio (%) | 184 |
Key management |
|
|---|---|
| Iain Ross | Chairman |
| James Garner | CEO |
